Form 4: Amgen Director Robert Eckert Reports Acquisition of 809 Shares Through Incentive Program

Amgen Inc. Director Robert Eckert has reported the acquisition of 809 shares of common stock, increasing his total beneficial ownership to 25,027 shares, as part of the company's Director Incentive Program.

Summary

• Robert Eckert, a Director of Amgen Inc. (AMGN), acquired 809 shares of common stock on May 23, 2025.
• The acquisition was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy Rule 10b5-1(c).
• These shares were granted as Restricted Stock Units (RSUs) under the Amgen Inc. 2009 Director Incentive Program, which vested immediately and are paid in shares on a one-to-one basis.
• The reported transaction price for these shares was $0, typical for RSU grants as a form of compensation.
• Following this transaction, Mr. Eckert's total beneficial ownership of Amgen common stock increased to 25,027 shares.
• The total beneficial ownership includes 3,384 Dividend Equivalents (DEs) granted under the Director Program, subject to a dividend reinvestment plan, and paid out in shares of common stock.

Sentiment

Score: 6

Explanation: The document reports a routine, expected compensation grant to a director, which is generally a neutral event but can be seen as slightly positive due to increased director alignment with shareholder interests. There are no negative implications.

Positives

• The acquisition of shares by a director, even if compensation, aligns the director's interests with those of shareholders, promoting long-term value creation.
• The transaction is part of a pre-existing, disclosed incentive program (Rule 10b5-1(c) plan), indicating a structured and transparent approach to executive compensation.

Future Outlook

This document, a Form 4, reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately."
• "Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule."
• "These shares include 3,384 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount."

Industry Context

This Form 4 filing reflects a common practice in the biotechnology and pharmaceutical industry, where director compensation often includes equity awards like Restricted Stock Units (RSUs). Such grants are designed to align the interests of directors with long-term shareholder value creation, a standard corporate governance practice across various sectors, including healthcare.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely accepted practice across major U.S. public companies, including those in the biotech and pharmaceutical sectors like Pfizer, Johnson & Johnson, and Merck.
• The immediate vesting of RSUs for directors, as seen here, is also common, though some companies may have staggered vesting schedules.
• The inclusion of Dividend Equivalents (DEs) on deferred RSUs is a standard feature in many equity incentive plans, ensuring that directors receive the economic benefit of dividends on their unissued shares.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Robert Eckert, a director, from Amgen Inc. as part of an incentive program constitutes a related party transaction, which is a common and disclosed practice for director compensation.

Stakeholder Impact

• Shareholders: The transaction increases the director's equity stake in the company, potentially aligning their interests more closely with long-term shareholder value. As a routine compensation event, it is not expected to have a significant direct impact on share price.

Key Dates

Keywords

Amgen, AMGN, Robert Eckert, Form 4, SEC filing, insider transaction, director compensation, stock acquisition, Restricted Stock Units, RSU, Dividend Equivalents, DEs, corporate governance, equity incentive plan